Skip to main content

Autoinflammatory

FDA has granted Rare Pediatric Disease Designation (RPDD) to a new proprietary investigational drug, 101-PCG-005, a type IA prodrug of dexamethasone targetsing CD206+ macrophages. The intended use is in systemic juvenile idiopathic arthritis (sJIA) or Still's disease .… https://t.co/ErNWlva9Nd https://t.co/gc8cPNs3H1
Dr. John Cush @RheumNow( View Tweet )

Don’t Buy Guitars (12.6.2024)

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
EULAR and the Paediatric Rheumatology European Society (PReS) and FDA now view systemic juvenile idiopathic arthritis and adult-onset Still’s disease as a single entity — Still’s disease; based on overlapping tests, clinical manifestations, complications & response to biologics… https://t.co/OHfcFymdPx https://t.co/Wm2ciKbMtY
Dr. John Cush @RheumNow( View Tweet )
Standardizing Still’s Disease Research: Global Data Harmonization Needed A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD).… https://t.co/ugsfRj2fnS https://t.co/UJmNvAMo1c
Dr. John Cush @RheumNow( View Tweet )

ACR24: Rheumatology Roundup

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article

​​Standardizing Still’s Disease Research: Global Data Harmonization Needed

A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). Analyzing 195 studies with over 18,000 patients, they found considerable variation

Read Article
COVID Associated Immune Disease Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24 https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7
Dr. John Cush @RheumNow( View Tweet )
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops? Check out my article: Taking the AI out of AutoImmunity https://t.co/d3ZNYWQaaQ @RheumNow #ACR24

Akhil Sood MD @AkhilSoodMD( View Tweet )

Long COVID outcomes in Autoimmune diseases (AID) Abstract 1897: - Long COVID symptoms higher among AID pts vs controls - vaccinated may have protective benefit @RheumNow #ACR24 https://t.co/2SEcbkxfcU
Akhil Sood MD @AkhilSoodMD( View Tweet )
A#2530 ANA reactive CD4 cells: elevated B cell help activation in SjD Unique autoreactive T cell cluster in SSc shows CD4+ TRAIL+ IFN type I - unique to SSc Leads to decrease activation of APCs, decrease CD4 T effector fxn @RheumNow #ACR24 https://t.co/4JnA3SpVM8
Eric Dein @ericdeinmd( View Tweet )
A#2531 @AlisaMueller CRISPR deletion of fibroblasts, gave cytokine activation to mimic inflamm Are there gene depletions that affect inflamm pathways? 👉SIX1 reduces inflamm potentiation 👉NFIL3 deletion promotes inflamm, degradation @RheumNow #ACR24 https://t.co/Nqghb5UaBR
Eric Dein @ericdeinmd( View Tweet )
Imaging in TAK Diagnosis @KQuinnRheum @RheumNow ⭐ Take homes ⭐ 👉location of renal artery stenosis (RAS) key to making Dx with proximal RAS in TAK 👉FDG PET -focal uptake in TAK vs diffuse in GCA 👉MRI good surrogate for disease activity where PET unavailable #ACR24 https://t.co/UWxTAZScIt
Patricia Harkins @DrTrishHarkins( View Tweet )

ACR 2024 - Day 2 Report

Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.

Read Article
We saw evidence for JAK use in GCA this conference... what about IL-1 inhibition? Double-blind RCT: Anakinra vs. PBO w/ similar GC taper in GCA pt NO difference in relapse rate at 26, 52 wks despite addition of Anakinra @RheumNow #ACR24 Abst1699 https://t.co/gUb0gGJjTG
Brian Jaros, MD @Dr_Brian_MD( View Tweet )
Comparison of infection risk across b/tsDMARDs in IA in real-world study Treatment with ➡️Rituximab ➡️JAKi ➡️Anti-IL6 assoc with ⬆️⬆️ risk of severe infection compared to TNFi A reminder to consider comorbidities & infection risk in selecting b/tsDMARDs Ab1716 #ACR24 @RheumNow

Mrinalini Dey @DrMiniDey( View Tweet )

Is #IL1 inhibition for 4 months a winner in #GCA —NOPE Anakinra daily 100mg sc 4/12 Underpowered but equal relapses and d/c #steroids not different #relapses esp after d/c #anakinra N=30 d/c due to #COVIDpandemic #1699 #ACR24 @RheumNow @ACRheum https://t.co/1TgloS5x8O
Janet Pope @Janetbirdope( View Tweet )
de Boysson et al. RCT anakinra in GCA. 30 patients. Week 52 relapse 53% in anakinra vs 46% in placebo. @RheumNow #ACR24 Abstr#1699 https://t.co/sqDWUlkXAX
Richard Conway @RichardPAConway( View Tweet )
#1165 📊 PBMCs of IIM patients with myocarditis(n=4) showed distinct gene expression v controls(n=4) v IIM alone(n=4)👇 💥 B-cell dysregulation may drive myocarditis in IIM 🎯Key immunological insights into🫀involvement in IIM #ACR24 @RheumNow @JuliePaikMD @jhrheumatology https://t.co/PceZUS929S
Caoilfhionn Connolly @CaoilfhionnMD( View Tweet )

If high +ANA and NO #rheumatic #disease LOOK 👀 at #LIVER #Autoimmune #hepatitis And #alcoholic #liver #dx #ACRBest #ACR24 @rheumnow abst#0627 https://t.co/EVLUyvpBfD

Janet Pope @Janetbirdope( View Tweet )
CV risk factors in rheumatic dz patients start in childhood. Patients with PMH of Kawasaki disease are at risk for rca/lmca aneurysms, thrombosis and stroke. Important to consider this with our history taking when pediatric patients transition to adult care! @RheumNow #ACR24 https://t.co/CIp8PjW4vD
Gabriela Martinez Zayas, MD @MartinezZayasMd( View Tweet )
Diagnosis and Management of Kawasaki Disease The journal Circulation has published a comprehensive overview called “Update on Diagnosis and Management of Kawasaki Disease,” summarizing data published since the 2017 American Heart Association Scientific Statement on Kawasaki… https://t.co/rS5bDneplO https://t.co/nZ0GeIQD0T
Dr. John Cush @RheumNow( View Tweet )
COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.… https://t.co/zlJrusJDM4 https://t.co/cuumClbN6b
Dr. John Cush @RheumNow( View Tweet )
New download available! Substitute Inflammatory Measures https://t.co/FiZSvvl5DA https://t.co/QwVefFLcHO
Dr. John Cush @RheumNow( View Tweet )

COVID-19 and Long-Term Risk of Autoimmune and Autoinflammatory Disorders

A Korean population based study found that people infected with COVID-19, especially severe COVID-19, had an increased risk of autoimmune and autoinflammatory connective tissue disorders.

While several observational studies have suggested an association between COVID-19 and future

Read Article
A Keto Diet for Autoimmune Disorders? Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis. https://t.co/7mX6Ue4FdX https://t.co/qtOwdKfqu4
Dr. John Cush @RheumNow( View Tweet )
×